Pinnaql, Inc., ("Pinnaql" or the "Company"), a 3 Boomerang Capital, LP ("3BC") portfolio company, today announced it has ...

The EMA has recommended updating Comirnaty 10 mg formulations, including JN.1, KP.2, and LP.8.1 versions, to allow COVID-19 vaccination in individuals aged 6 months or older.

MM‐LP@COL nanovesicles were fabricated by fusing macrophage membranes with liposomes. Physicochemical characterization was performed using DLS, TEM, and FRET analysis. Cytokine‐scavenging capacity was ...

The US Supreme Court declined to take up Purdue Pharma LP’s bid to undo the invalidation of patents covering an abuse-resistant formulation of OxyContin. Purdue’s April cert petition contended that ...

Abstract: The product delivery process is a set of steps to transport a product of an origin to a delivery point. Nowadays, there are different platforms or software based on classical algorithms for ...

The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...

The updated vaccine is expected to be available in the coming days. The US Food and Drug Administration (FDA) has approved the Comirnaty 2025-2026 COVID-19 vaccine formulation, which targets the ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

On July 30, 2025, Moderna announced that the European Commission (EC) granted marketing authorization for the updated formulation of Moderna’s COVID-19 vaccine Spikevax®. The updated vaccine targets ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the ...